Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00825188 · ClinicalTrials.gov registry record · NA
A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives
A NA study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00825188 is a NA study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT00825188, a NA study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Obesity and hypertension are independent risks for congestive heart failure (CHF) and chronic kidney disease. In obesity induced hypertension, the most common cause of human essential hypertension, the potential importance of mineralocorticoid receptor blockade has not been widely investigated. We propose to test the hypothesis that eplerenone reduces metabolic demand, improves cardiac function and attenuates glomerular hyperfiltration and microalbuminuria in obese patients. Our specific aims are to assess changes in basal metabolic rate, cardiac and renal function in obese hypertensive subjects treated with eplerenone compared to amlodipine.
Interventions
- DRUG eplerenone
- DRUG amlodipine
- DRUG eplerenone, amlodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00825188
The ClinicalTrials.gov registry entry for NCT00825188 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which eplerenone is the first listed.
NCT00825188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00825188 about?
NCT00825188 is a clinical study titled "A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives". Obesity and hypertension are independent risks for congestive heart failure (CHF) and chronic kidney disease. In obesity induced hypertension, the most common cause of human essential hypertension, the potential importance of mineralocorticoid receptor blockade has not been widely investigated. We p...
What is the current status of trial NCT00825188?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2009-01. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00825188?
The interventions under investigation include: eplerenone (DRUG), amlodipine (DRUG), eplerenone, amlodipine (DRUG).
Who is sponsoring clinical trial NCT00825188?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.